Home2018-11-15T16:29:29+00:00

Liver Testing Through a New Investigative Tool

liver health image

Function Matters

HepQuant: A minimally invasive assessment of chronic liver disease

HepQuant Test to Measure Liver

New Investigative Tools to Evaluate the Liver

HepQuant Research Center and Lab

assessment of chronic liver disease

Novel technology for minimally invasive

Liver Function Tests: Breaking Through Conventional Thinking About Liver Health Testing

HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.

Recent Events

  • HepQuant attended the AASLD Liver Meeting in San Francisco, Nov. 9 – 13th. The event is typically attended by more than 9,500 hepatologists and hepatology health professionals from across the nation and around the world.   (More info.) The company presented 2 posters:

“Defining and Monitoring Liver Disease in Chronic Hepatitis C:  A Comparison of the Disease Severity Index (DSI) from the HepQuant SHUNT test with Ishak Fibrosis (IFS) from Liver Biopsy.” Everson GT, Helmke SM.  Hepatology 2018;68:910A. Annotation: This study suggests that DSI may be more sensitive than IFS in measuring serial changes in disease in patients with chronic hepatitis C.

“Defining Disease Severity and Measuring Progression in Primary Sclerosing Cholangitis (PSC):  A Comparison of the Disease Severity Index (DSI) from the HepQuant SHUNT Test with Serum Alkaline Phosphatase (Alk Phos).”  Helmke SM, Everson GT. Hepatology 2018;1087A. Annotation: This study suggests that DSI may be more sensitive than Alk Phos in measuring serial changes in disease in patients with PSC.


Recently Attended

NASH liver disease biomarkers image

International Workshop on NASH BiomarkersHepQuant’s Chief Business Development Officer Brad Everson and Chief Scientific Officer Dr. Steve Helmke recently attended the 3rd edition of the International Workshop on NASH Biomarkers in Washington, DC.

liver test for pharmaceutical clinical trials

Recently Presented

HepQuant presented a poster at Nash Summit 2018: “Identifying Potential Subjects for NASH Clinical Trials Using the HepQuant Quantitative Liver Tests”

HepQuant was discussed by at the October 2017 AASLD Meeting during an NAFLD Debrief.  For AASLD member access to the presentation, please click here.

Here is a link to our 2017 AASLD presentation on “Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test.”

Highlights from the 2nd Annual NASH Summit – Boston | April 2018

NASH Summit 2018 - Dr Everson HepQuant

CONTACT US

These links are for informational purposes only and do not imply that HepQuant has any formal relationships with the organizations, nor do the organizations endorse HepQuant or its liver function tests.